Klotho: The Longevity Protein

Klotho is a protein named after Clotho, the Greek Fate who spins the thread of life — a fitting choice, because its discovery in 1997 came from a mouse strain that aged dramatically faster when the gene was disrupted. Mice lacking klotho develop a syndrome resembling accelerated human aging: shortened lifespan, arteriosclerosis, osteoporosis, skin atrophy, and cognitive decline. Conversely, overexpressing klotho extends lifespan in mice. This bidirectional effect established klotho as one of the most compelling single-gene regulators of aging identified to date.

What klotho is

Klotho exists in more than one form. The best-studied is alpha-klotho, a transmembrane protein expressed most highly in the kidney and choroid plexus of the brain. Its extracellular domain can be cleaved and released into blood, cerebrospinal fluid, and urine as "soluble klotho," which acts as a circulating, hormone-like factor with effects on distant tissues. Two related proteins, beta-klotho and gamma-klotho, participate in distinct signaling systems, including metabolic regulation.

Circulating klotho levels decline with age and are reduced in chronic kidney disease, cardiovascular disease, and several age-related conditions — which is why klotho is often described as an "aging-suppressor" whose loss permits age-related dysfunction to accelerate.

Core functions

Phosphate and vitamin D metabolism

Membrane alpha-klotho acts as an obligate co-receptor for fibroblast growth factor 23 (FGF23), a bone-derived hormone that regulates phosphate excretion and vitamin D metabolism. Without klotho, FGF23 signaling fails, phosphate handling becomes dysregulated, and the resulting mineral imbalance contributes to vascular calcification and tissue aging. This FGF23–klotho axis is central to the bone-kidney-vascular crosstalk that goes awry in chronic kidney disease.

Protection against oxidative stress and senescence

Soluble klotho influences several intracellular pathways associated with longevity. It modulates insulin/IGF-1 signaling (dampening it, consistent with the longevity effects seen when this pathway is reduced), enhances resistance to oxidative stress, and suppresses signaling that promotes fibrosis and cellular senescence. These actions connect klotho to other hallmarks of aging covered elsewhere on this site, including senescence and oxidative stress.

Cognitive function

Klotho is expressed in the brain, and higher klotho levels are associated with better cognitive performance in both animal models and human observational studies. Experimentally, raising klotho has enhanced synaptic function and cognition in mice, and a common klotho gene variant (KL-VS) associated with higher klotho has been linked to better cognition in some human studies. This has made klotho a target of interest for neurodegeneration and cognitive aging.

Klotho and peptides

Klotho itself is a large protein, not a small therapeutic peptide, and there is no approved klotho drug or validated way to meaningfully raise klotho with a supplement. This is an important caution: klotho is frequently invoked in longevity marketing, but exogenous klotho therapy remains experimental.

Where klotho intersects the peptide world is conceptual. Longevity-oriented peptides discussed elsewhere on this site — mitochondrial peptides like MOTS-c and SS-31, and bioregulators like Epitalon — target overlapping hallmarks of aging (mitochondrial function, oxidative stress, cellular maintenance) rather than the klotho pathway directly. Exercise, which raises klotho in some studies, remains the most reliable lever available today. Claims that a specific peptide "boosts klotho" in humans should be treated skeptically absent controlled data.

Research directions

Active areas include klotho as a biomarker of biological aging and kidney health, klotho-based or klotho-mimetic approaches for chronic kidney disease and cognitive decline, and dissecting how the FGF23–klotho axis drives cardiovascular calcification. Delivering a large protein across the blood-brain barrier and achieving durable systemic exposure are significant hurdles that keep klotho firmly in the research stage.

Key takeaways

• Klotho is an aging-suppressor protein; its loss accelerates aging in animal models and its levels decline with age and disease.
• It functions as the FGF23 co-receptor (phosphate/vitamin D control), dampens insulin/IGF-1 signaling, resists oxidative stress and senescence, and supports cognition.
• There is no approved klotho therapy and no validated supplement that reliably raises human klotho; exercise is the most evidence-supported lever.
• Longevity peptides target adjacent aging hallmarks, not the klotho pathway directly — treat "klotho-boosting" peptide claims with skepticism.